Abarelix

Abarelix (also known as Plenaxis, PPI-149, abarelixum, Abarelix Acetate) is a anti-aging research peptide. Abarelix is a gonadotropin-releasing hormone receptor antagonist approved by the FDA for certain prostate cancer cases.

Abarelix is a gonadotropin-releasing hormone (GnRH) receptor antagonist. It functions by blocking the GnRH receptor, thereby reducing the production of sex hormones. Abarelix is FDA-approved and has reached Phase 4 clinical trials for neoplasms and Phase 3 for castration-resistant prostatic neoplasms. Research on abarelix has focused on its role as a first-in-class GnRH antagonist for prostate cancer, with studies evaluating its therapeutic potential and clinical applications.

1 Mechanism of action

Gonadotropin-releasing hormone receptor antagonist (antagonist)

Primary targets: Gonadotropin-releasing hormone receptor

2 Reported effects

Effects below are those reported in the published literature cited on this page. They are not claims of clinical benefit and not medical advice.

2.1 Indicated / studied for

• Neoplasms
• Prostatic Neoplasms, Castration-Resistant

3 Chemical and physical properties

4 Research studies (8)

1. Gateways to Clinical Trials. June 2002
   Methods and findings in experimental and clinical pharmacology (2002) · Review
2. Gateways to clinical trials
   Methods and findings in experimental and clinical pharmacology (2002) · Review
3. Technology evaluation: Abarelix, Praecis pharmaceuticals
   Current opinion in molecular therapeutics (2000) · RCT
4. Abarelix: abarelix-depot-F, abarelix-depot-M, abarelix-L, PPI 149, R 3827
   Drugs in R&D (2003) · Review
5. Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer
   Future oncology (London, England) (2006) · Review
6. Therapeutic outcomes of the LHRH antagonists
   Expert review of pharmacoeconomics & outcomes research (2017) · Review
7. Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer
   Expert opinion on pharmacotherapy (2004) · Review
8. GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy
   Pharmaceuticals (Basel, Switzerland) (2024) · Review

5 Safety and risk profile

5.1 Regulatory status

Abarelix is currently classified as FDA approved. Approval applies to specific clinical indications and dosing; research-grade material is not the approved product.

6 Frequently asked questions

What is Abarelix used for?

Abarelix is used for the treatment of certain neoplasms, specifically in cases of prostatic neoplasms that are castration-resistant. It is an FDA-approved medication.

How does Abarelix work?

Abarelix functions as a gonadotropin-releasing hormone (GnRH) receptor antagonist. By blocking the GnRH receptor, it reduces the body's production of sex hormones, which can be beneficial in hormone-sensitive cancers.

Is Abarelix FDA approved?

Yes, Abarelix is FDA approved. It received its first approval in 2003 and has been studied extensively for its indicated uses.

What class of drug is Abarelix?

Abarelix is classified as a gonadotropin-releasing hormone receptor antagonist. This means it works by blocking the receptors for GnRH, a hormone involved in the regulation of sex hormones.

7 References

1. Abarelix — compound summary PubChem. View source
2. Abarelix — molecule record ChEMBL. View source
3. Abarelix — published literature (55 records) PubMed. View source

8 See also

• Peptide encyclopedia index
• Peptide reconstitution calculator
• Glossary of peptide research terms